CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A Research Letter
| Authors: | Stanchina, M.; Pastore, A.; Devlin, S.; Famulare, C.; Stein, E.; Taylor, J. |
| Title: | CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A |
| Abstract: | We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conjugate SGN-CD33A. This genotype, for the CD33 splice site SNP rs12459419, was not associated with clinical response (30% CR/CRi in both groups), event-free survival, or overall survival. © 2019 The Author(s). |
| Keywords: | acute myeloid leukemia; antibody-drug conjugate; cd33 |
| Journal Title: | Journal of Hematology & Oncology |
| Volume: | 12 |
| ISSN: | 1756-8722 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2019-08-22 |
| Start Page: | 85 |
| Language: | English |
| DOI: | 10.1186/s13045-019-0771-0 |
| PROVIDER: | scopus |
| PMCID: | PMC6704571 |
| PUBMED: | 31439003 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 4 September 2019 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work